NRX Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings
NRXP·Reported November 14, 2024·After market close
Diluted EPS came in at $-0.15, beat the $-0.81 consensus by $0.66.
Diluted EPS
$-0.15beat by $0.66
Consensus: $-0.81
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about NRX Pharmaceuticals, Inc.'s Q3 2024 earnings report.
NRX Pharmaceuticals, Inc. (NRXP) reported Q3 2024 earnings on November 14, 2024 after market close.
NRX Pharmaceuticals, Inc. reported diluted EPS of $-0.15 for Q3 2024.
EPS beat the consensus estimate of $-0.81 by $0.66.
You can read the 10-Q periodic report (0001437749-24-035289) directly on SEC EDGAR. The filing index links above go to sec.gov.